Press Releases

Date Title
Toggle Summary Aeglea BioTherapeutics Doses First Uveal and Cutaneous Melanoma Patients in Phase 1 Cohort Expansions with Pegzilarginase
Topline Safety and Clinical Activity Data Expected in 4Q 2018 AUSTIN, Texas , March 08, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases
Toggle Summary Aeglea BioTherapeutics to Present Adult Repeat Dose Data at 2018 Annual Meeting of The Society for Inherited Metabolic Disorders
Company to Hold Clinical and Corporate Update Conference Call at 8:00 a.m. ET on Tuesday, March 13 AUSTIN, Texas , March 06, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for
Toggle Summary Aeglea BioTherapeutics to Present Preclinical Data at 2018 Keystone Symposia Tumor Metabolism Conference
AUSTIN, Texas , Jan. 18, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to the discovery and development of engineered human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that it will present a poster
Toggle Summary Aeglea BioTherapeutics to Present at BMO Capital Markets Prescriptions for Success Healthcare Conference
Company to Webcast Presentation on Thursday, December 14 at 8:30 a.m. ET AUSTIN, Texas , Dec. 07, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to the discovery and development of engineered human enzyme therapeutics for patients with rare
Toggle Summary Aeglea BioTherapeutics Doses First Pediatric Patient with Arginase 1 Deficiency in its Phase 1/2 Trial with Pegzilarginase (AEB1102)
Clinical Agreement Reached with FDA to Enable Pediatric Dosing AUSTIN, Texas , Nov. 29, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to the discovery and development of engineered human enzyme therapeutics for patients with rare genetic
Toggle Summary Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results
AUSTIN, Texas , Nov. 07, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. , (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today provided a corporate update and reported
Toggle Summary Aeglea BioTherapeutics to Present Preclinical Data at 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting
AUSTIN, Texas , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that it will deliver a poster
Toggle Summary Aeglea BioTherapeutics Announces Clinical Collaboration with Merck to Evaluate the Combination of Aeglea’s AEB1102 (pegzilarginase) with Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Small Cell Lung Cancer
AUSTIN, Texas , Oct. 16, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. , (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced it has entered into a clinical
Toggle Summary Aeglea BioTherapeutics Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for the Treatment of Arginase 1 Deficiency
Topline data is expected in second half of 2018 AUSTIN, Texas , Sept. 06, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. , (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer,
Toggle Summary Aeglea BioTherapeutics to Present at the 2017 Wells Fargo Healthcare Conference
AUSTIN, Texas , Aug. 31, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that management will be presenting
Toggle Summary Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial Results
AUSTIN, Texas , Aug. 09, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. , (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today provided a corporate update and reported
Toggle Summary Aeglea BioTherapeutics Announces Leadership Change
Anthony Quinn, M.B Ch.B, Ph.D., Aeglea board member, former head of R&D at Synageva BioPharma, named interim CEO AUSTIN, Texas , July 20, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field
Toggle Summary Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer
AUSTIN, Texas , July 10, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. , (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that it has appointed James
Toggle Summary Aeglea BioTherapeutics Prices Public Offering of Common Stock
AUSTIN, Texas , June 06, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. , (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced the pricing of its underwritten
Toggle Summary Aeglea BioTherapeutics Announces Proposed Public Offering of Common Stock
AUSTIN, Texas , June 05, 2017 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat rare genetic diseases and cancer, today announced that it has commenced an